News Headlines Article

New articles highlight rift over statins
Los Angeles Times

A simmering scientific dispute over statins, the cholesterol-lowering prescription drugs that rake in some $26 billion a year for their makers, heated up Monday with an exchange of published volleys that drove back the reputation of the widely prescribed medications in one area even as it advanced their stature in another.

A meta-analysis — a review of previous studies — published in the Archives of Internal Medicine found that statins do not lower death rates among patients with risk factors but no evidence of established cardiovascular disease who take them as a preventive measure.